Drug Profile


Alternative Names: F-13640; NLX 112

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pierre Fabre
  • Developer Neurolixis
  • Class Antiparkinsonians; Non-opioid analgesics; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Preclinical Drug-induced dyskinesia
  • Discontinued Cancer pain; Neuropathic pain

Most Recent Events

  • 24 Jan 2018 Preclinical development is ongoing in USA
  • 14 Jun 2017 Pharmacodynamics data from preclinical trials in Drug-induced dyskinesia released by Neurolixis
  • 06 Feb 2015 Befiradol is available for licensing as of 06 Feb 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top